De-Sone LA injection and Pexidartinib
Determining the interaction of De-Sone LA injection and Pexidartinib and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration of pexidartinib with moderate CYP450 3A4 inducers may decrease the plasma concentrations and therapeutic effects of pexidartinib. The proposed mechanism is induction of CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of pexidartinib. Concomitant administration of rifampin, a strong CYP450 3A4 inducer, decreased pexidartinib peak plasma concentration (Cmax) and systemic exposure (AUC) by 33% and 65%, respectively. No data are available regarding the effects that other, less potent CYP450 3A4 inducers may have on the pharmacokinetics of pexidartinib. MANAGEMENT: Caution is advised if pexidartinib is used with moderate CYP450 3A4 inducers. It is unknown if pexidartinib will require a dosage adjustment if coadministered with a moderate CYP450 3A4 inducer. Clinical and laboratory monitoring of pexidartinib should be considered whenever a moderate CYP450 3A4 inducer is added to or withdrawn from therapy. Patients should be monitored for diminished therapeutic effects. References "Product Information. Turalio (pexidartinib)." Daiichi Sankyo, Inc., Parsippany, NJ.
Professional:MONITOR: Coadministration of pexidartinib with moderate CYP450 3A4 inducers may decrease the plasma concentrations and therapeutic effects of pexidartinib. The proposed mechanism is induction of CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of pexidartinib. Concomitant administration of rifampin, a strong CYP450 3A4 inducer, decreased pexidartinib peak plasma concentration (Cmax) and systemic exposure (AUC) by 33% and 65%, respectively. No data are available regarding the effects that other, less potent CYP450 3A4 inducers may have on the pharmacokinetics of pexidartinib.
MANAGEMENT: Caution is advised if pexidartinib is used with moderate CYP450 3A4 inducers. It is unknown if pexidartinib will require a dosage adjustment if coadministered with a moderate CYP450 3A4 inducer. Clinical and laboratory monitoring of pexidartinib should be considered whenever a moderate CYP450 3A4 inducer is added to or withdrawn from therapy. Patients should be monitored for diminished therapeutic effects.
- "Product Information. Turalio (pexidartinib)." Daiichi Sankyo, Inc., Parsippany, NJ.
Generic Name: dexamethasone
Brand name: De-Sone LA, Dexacen-4, Dexasone, Dexasone LA, Solurex, Solurex LA, Baycadron, Dexamethasone Intensol, DexPak 10 Day Taperpak, DexPak 13 DayTaperpak, DexPak 6 DayTaperpak, Decadron, DexPak, TaperDex, Zema-Pak, ZoDex, Zonacort
Synonyms: De-Sone LA (injection)
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- De-Sone LA injection-Pexidartinib Hydrochloride
- De-Sone LA injection-Pfizerpen
- De-Sone LA injection-Pharaon Tea
- De-Sone LA injection-Pharmorubicin Pfs
- De-Sone LA injection-Phazyme
- De-Sone LA injection-Phazyme Liquid Gas Relief, Maximum Strength
- Pexidartinib-Deblitane
- Pexidartinib-Decadron
- Pexidartinib-Decadron Elixir
- Pexidartinib-Decara
- Pexidartinib-Decavac
- Pexidartinib-Decavac (Td) Td
De-Sone LA injection - Pexidartinib 
De-Sone LA injection - Pexidartinib 
De-Sone LA injection - Pexidartinib 
De-Sone LA injection - Pexidartinib 
De-Sone LA injection - Pexidartinib 
De-Sone LA injection - Pexidartinib 
De-Sone LA injection - Pexidartinib 
De-Sone LA injection - Pexidartinib 
De-Sone LA injection - Pexidartinib 
De-Sone LA injection - Pexidartinib 
De-Sone LA injection - Pexidartinib 
De-Sone LA injection - Pexidartinib